NHS South East rolls out DERM skin cancer AI that can discharge patients on its own
Skin Analytics' DERM goes live across all 18 NHS trusts in south-east England from this autumn, covering another 9 million people over three years; the company calls it the largest deployment of autonomous medical AI in NHS history. DERM analyses images of a lesion taken after a suspected skin cancer referral and, when it judges the lesion benign, lets the NHS discharge the patient at the triage stage, while higher-risk cases are sent faster to a specialist. Skin Analytics says DERM is the first and only AI certified for autonomous use under a Class III CE mark, and reports it has assessed more than 250,000 patients and found over 25,000 cancers, with its own monitoring data putting skin cancer rule-out at 99.5% and detection at about 98%.
If autonomous triage holds up over the three-year rollout, it becomes an important reference point for how regulators treat medical AI allowed to clear patients without a clinician's review.

NHS England’s South East region is rolling out an AI that can discharge patients with harmless skin lesions without a dermatologist seeing them. DERM, made by London-based Skin Analytics, goes live in all 18 NHS trusts there from this autumn. It will cover another 9 million people.
Skin Analytics announced the rollout on Wednesday and called it the largest deployment of autonomous medical AI in NHS history. The rollout runs for three years.